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© 2010 The Japan Society of Histochemistry and Cy- Myotonic dystrophy (DM1) is known to be an adult-onset muscular dystrophy caused by
the expansion of CTG repeats within the 3' untranslated region of the dystrophin myotonin
protein kinase (DMPK) gene. The clinical features of DM1 include CNS symptoms, such as
cognitive impairment and personality changes, the pathogenesis of which remains to be
elucidated. We hypothesized that the distribution of neuropathological changes might be
correlated with the extent of the length of the CTG repeats in the DMPK genes in DM1
patients. We studied the neuropathological changes in the brains of subjects with DM1 and
investigated the extent of somatic instability in terms of CTG repeat expansion in the differ-
ent brain regions of the same individuals by Southern blot analysis. The neuropathological
changes included état criblé in the cerebral deep white matter and neurofibrillary tangles
immunoreactive for phosphorylated tau in the hippocampus and entorhinal cortex, both of
which were compatible with the subcortical dementia in DM1 patients. However, the length
of the CTG repeats did not correlate with the regional differences in the extent of neuro-
pathological changes. Our data suggested that pathomechanisms of dementia in DM1 might
be more multifactorial rather than a toxic gain-of-function due to mutant RNA.
Key words: myotonic dystrophy (DM1), dementia, dystrophin myotonin protein kinase, CTG
repeats, neuropathology
I. Introduction
Myotonic dystrophy (DM1) is the most common, auto-
somal dominant form of adult muscular dystrophy, affecting
around 1 in 8000 individuals. DM1 is caused by the expan-
sion of CTG repeats within the 3' untranslated region (UTR)
of the dystrophin myotonin protein kinase (DMPK) gene
[3, 4]. Normal individuals have less than 50 CTG repeats
whereas DM1 patients have hundreds or even thousands.
The severity and age of onset of DM1 correlate well with
the length of the repeats. In addition, somatic mosaicism of
the expansion of CTG repeats has been observed in different
organs of the same individuals with DM1.
The clinical features of DM1 include muscle weakness,
myotonia, cardiac arrhythmia, endocrinopathy, such as
frontal baldness and insulin resistance, cataracts, and CNS
symptoms. CNS symptoms include cognitive impairment
and particular personality changes [2, 21]. Although no
detailed studies have as yet been reported, these CNS
symptoms should be based upon specific neuropathologi-
cal changes.
Recent molecular genetic studies suggested that the
underlying pathological mechanism of both the myopathy
and the CNS symptoms associated with DM1 is a toxic
gain-of-function due to mutant RNA [5, 6, 11, 17, 22, 31–
33]. The CUG-expanded transcripts of the mutant allele areItoh et al. 150
retained in the cell nuclei to form intranuclear inclusions,
which then compromise the regulation of alternative splicing
for a subset of neuronal transcripts [7, 10, 14, 15, 18, 19].
We hypothesized that the distribution of neuropatho-
logical changes might be correlated with the extent of the
length of the CTG repeats in DMPK genes in DM1 patients.
In order to verify our hypothesis, we studied the neuro-
pathological changes found in the brains of subjects with
DM1 (M/F=5/6) and investigated the extent of somatic
instability in terms of the expansion of CTG repeats in the
different brain regions of the same individuals, employing
the Southern blot analysis method. We found état criblé
in the cerebral deep white matter, lesions that should be
responsible for the subcortical dementia in subjects with
DM1. However, no correlation was demonstrated between
the extent of the length of the CTG repeats and the patho-
logical changes.
II. Materials and Methods
Clinical information
Eleven patients were enrolled in this study. Age (mean:
60.4 (50–69) years old) and gender (M/F=5/6) are described
in Table 1. All of the patients studied had a clinical history
of dementia for several years before death. None of them
had a history of hypertension.
Neuropathological examinations
Ten autopsied brains with DM1, each with a post-
mortem time within 3 hr, were studied (Table 1). After
weighing, the brains were cut at the median plane and the
left hemisphere was fixed with buffered formalin for histo-
logical analyses and the right side was frozen for molecular
analyses. This study was approved by the Ethics Committee
both at Kyoto Prefectural University of Medicine and
the National Hospital Organization, Hyogo-Chuo National
Hospital, and all the procedures for tissue sampling and
DNA analyses were in accord with the guidelines for
Genome Research issued by the Japanese Government.
After fixation, paraffin-embedded brain sections were
processed for staining with hematoxylin-eosin (HE), Klüver-
Barrera (KB), silver impregnation (Gallyas-Braak, Bodian),
and for immunohistochemistry using the PAP method.
The primary antibodies used were: Neurofilament, phos-
phorylated (1:100, United States Biological, Swampscott,
MA, USA), MAP2 (1:1000, Chemicon/Millipore, Billerica,
MA, USA), GFAP (1:1000, Chemicon/Millipore), Aβ1-40/
42 (1:100, Chemicon/Millipore), Human PHF-Tau (clone
AT8, 1:200, Innogenetics N.V./S.A., Gent, Belgium), ubiq-
uitin (1:1000, Abcam, Cambridge, UK), α-synuclein (1:3000,
Chemicon/Millipore), CD34 (clone QBEND-10, 1:1000,
Abcam) and α-SMA (clone 1A4, 1:2000, Sigma Chemical
Co. St Louis, MO, USA). The areas of the brain studied were
the frontal, orbital, parietal, temporal, and occipital cortices
and white matter, hippocampus, entorhinal cortex, basal
ganglia such as nucleus caudatus, putamen, globus pallidus,
nucleus lateralis and medialis of the thalamus, tegmentum,
nucleus raphe dorsalis, substantia nigra of the midbrain,
locus coeruleus, reticular formation and nuclei pontis of
the pons, reticular formation and nucleus olivaris inferior of
the medulla oblongata, cerebellar cortex and white matter,
nucleus dentatus and pedunculus cerebellaris and the entire
length of the spinal cord. Semiquantitative study was per-
formed on the number or the extent of pathological changes
and evaluated as follows: +: moderate or frequent (localized
in the entorhinal cortex for NFT, or < approximately 2/mm2
for Lewy bodies), ++: severe or very frequent (spread to
the amygdala and presubiculum, subiculum and CA1 of the
hippocampus for NFT, > approximately 2/mm2 for Lewy
bodies).
DNA analyses
Genomic DNA was prepared from the brain tissues
(n=5) according to a standard protocol as previously report-
ed [4, 16]. The length of the CTG repeats was analyzed in
the tissue specimens obtained from the contralateral side of
the brain, but all of the areas studied corresponded to those
used for the neuropathological examinations. In each case,
Table 1. Summary of clinical and neuropathological findings from analysed cases
NFT: Neurofibrillary tangle; RF: Reticular formation.
*: DNA analysed.
+: moderate/frequent; ++: severe/very frequent.
CASE 1* 2 3 4* 5* 6* 7 8 9* 10 11 Frequency/Average
Age (years old) 50 55 58 59 61 61 62 62 63 64 69 60±5
G e n d e r M MFMFM MFFFF M / F = 5 / 6
D e m e n t i a +++++++++++ 1 0 0 %
H y p e r t e n s i o n ––––––––––– 0 %
Brain weight (g) 1460 1230 900 1180 900 1200 1080 910 1060 1140 960 1092±174
N e u r o n a l  l o s s  ( c o r t e x ) ––+–+––++++ 5 5 %
É t a t  c r i b l é +++++++++++ 1 0 0 %
NFTs + ++ + ++ + + + ++ ++ + ++ 100%
S e n i l e  p l a q u e s ––––––––––– 0 %
L e w y  b o d i e s –– + + –––––––+ 1 8 %
N F T - l i k e  i n  R F ––+–+––++–+ 4 5 %Neuropathology and CTG Repeats in MD1 151
the size of the expansion of the CTG repeats at the DMPK
locus was determined by Southern blot analysis of EcoRI-
and  BglI-digested DNA obtained from the tissue, using
cDNA25 as a probe. Pulse-field gel electrophoresis (PFGE)
was performed on the CHEF-DR-II system (Bio-Rad,
Hercules, CA, USA) as reported elsewhere [4, 16]. In
brief, eight μg of digested DNA fragments in buffer was
added to each sample well. SeaKem GTG agarose gel (FMC
BioProducts, Rockland, ME) of 0.7% was set in a chamber
containing standard Tris buffer kept at 14°C. The driving
conditions of the PFGE were: 120 V, 70 mA, pulse time
of 1 sec ramped up to 5 sec, and a run time of 20 hr, accord-
ing to the manufacturer’s instructions.
III. Results
Neuropathological examinations
Macroscopically, the brains showed diffuse atrophy
with a normal gyral configuration except for case 1 (10/11
cases, Fig. 1A). The proportion of the brain, cerebellum
and brainstem was normal. Mild to moderate symmetrical
ventricular dilatation with a decreased volume of the white
matter was identified on the cut sections (10/11 cases,
Fig. 1B). The basal forebrain showed dilatation of the
perivascular space. Microscopically, the deep white matter
in the frontal, orbital, temporal, parietal, and occipital lobes
showed état criblé, namely dilated perivascular spaces (type
III), loss of adjacent axons and myelin, capillary hyaliniza-
tion and fibrillary gliosis (11/11 cases, Fig. 2A–D). Small to
medium-sized arteries showed a loss of smooth muscles in
the tunica media associated with a collection of perivascular
CD34-immunoreactive pericytes or microglia and numerous
corpora amylacea (Fig. 2E, F). The cerebral cortices showed
a normal cytoarchitecture with mild neuronal loss (6/11
cases) or without neuronal loss (5/11 cases). No apparent
neuronal loss was found in the CA1 of the hippocampus,
subiculum and presubiculum, but there was a mild neuronal
loss in the entorhinal cortex. A moderate number of neuro-
fibrillary tangles, showing immunoreactivity for phospho-
rylated tau protein, were observed in the amygdala, CA1,
presubiculum and subiculum of the hippocampus, and in the
entorhinal cortex (11/11 cases, Fig. 3A, B). Many ghost tan-
gles were observed in the superficial layer of the entorhinal
cortex. Enlarged perivascular spaces and abundant corpora
amylacea were often observed in the substantia innominata.
Senile plaques, immunoreactive for Aβ, were not observed
in all cases. No apparent neuronal loss was observed in the
nucleus caudatus and putamen. Apparent calcification in
the vessel walls was sometimes observed in the lateral and
medial segments of the globus pallidus (6/11 cases). Cyto-
plasmic eosinophilic inclusions were seen in the thalamic
nuclei in 2/11 cases (Fig. 3E), mild neuronal loss, gliosis and
Lewy bodies were observed in the substantia nigra and locus
coeruleus in 2/11 cases (Fig. 3C, D), mild neuronal loss and
tangled masses of fibrils were observed in the reticular
formation of the brainstem in 5/11 cases (Fig. 3F, G). In the
pigmented neurons of the substantia nigra, an increased
number of intranuclear Marinesco bodies, round to oval, and
immunoreactive for ubiquitin were found (11/11 cases). No
apparent neuronal loss was detected in the nuclei pontis,
nucleus olivaris inferior, Purkinje cells and granule cells of
the cerebellum, and the nucleus dentatus. The spinal cord
showed no loss of neurons, axons, or myelin.
DNA analyses (Table 2)
The normal allele showed the same size in all the
analyzed brain regions in the DM1 cases, with a single
strong band at 8.6 and 9.8 kilobases (kb) after EcoRI and
3.4 kb after BglI digestion. The expanded allele showed
smear-like broad bands at around 18.0–23.9 kb after EcoRI
and 10–14.5 kb after BglI digestion in all of the brain
regions analyzed except for the cerebellar cortex and
nucleus dentatus, where the expanded repeat was larger
than that of the normal allele, but much smaller than the
Fig. 1. Macroscopic findings of the brain from myotonic dystrophy patients. A: lateral view. B: coronal sections at the level of basal ganglia and
thalamus. Bar=2 cm.Itoh et al. 152
Fig. 2. Deep white matter showing état criblé and hyalinized vessels. Marked dilatation of perivascular spaces (A, B), myelin pallor of
adjacent perivascular areas (C), hyalinized vessels (D), showing loss of smooth muscle in the tunica media (E) and extravasation of CD34-
immunoreactive cells (F). A: HE stain, B, C, D: Klüver-Barrera stain, E: immunohistochemistry for α-SMA, F: immunohistochemistry for
CD34. Bar=500 μm (A), 250 μm (B), 65 μm (C, D), 35 μm (E, F).Neuropathology and CTG Repeats in MD1 153
expanded repeats in other brain regions. In addition, the
bands of the expanded allele in the cerebellar cortex and
nucleus dentatus were intense and broad, not smeared,
which indicated that less somatic mosaicism is present in
these areas. Table 2 shows the ratios of expanded allele size
to normal allele size (as expanded ratios). The expanded
ratio of the cerebellum was significantly lower than that
of the other 22 various brain regions (p<0.01, one-way
ANOVA). There were no significant differences in ex-
panded ratios among all brain regions analysed except for
the cerebellum.
The size of the expanded allele showed a similar smear-
like band at around 20.0–26.4 kb after EcoRI and 10–14.5 kb
after  BglI digestion in the skeletal muscle, heart, liver,
spleen, pancreas, and testis. The largest expanded repeat was
observed in the spleen where a larger somatic mosaicism
was present.
Fig. 3. Miscellaneous neuropathological findings in brains with myotonic dystrophy. Abundant neurofibrillary tangles immunoreactive for
phosphorylated tau in the entorhinal cortex (A, B), brain-stem type Lewy bodies in the substantia nigra and locus coeruleus immunoreactive
for α-synuclein (C, D), eosinophilic cytoplasmic inclusion in the thalamic nuclei (E) and tangle-like inclusions in the nucleus raphe dorsalis (F)
and in the reticular formation of the medulla oblongata (G). A: Bodian stain, C, E, F, G: HE stain, B: immunohistochemistry for phospho-
rylated tau, D: immunohistochemistry for α-synuclein. Bar=130 μm (A), 50 μm (B), 15 μm (C–G).Itoh et al. 154
IV. Discussion
The present study demonstrated detailed neuropatho-
logical changes in DM1 brains, including neurofibrillary
tangles (NFT) immunoreactive for phosphorylated tau
protein localized in the CA regions of the hippocampus,
amygdala and the entorhinal cortex, and état criblé (indica-
tive of perivascular ischemic changes) in the cerebral deep
white matter. The other pathological changes observed
frequently, but regarded as nonspecific, were as follows:
Lewy bodies and increased Marinesco bodies in the pig-
mented neurons of the substantia nigra, NFT-like neuronal
inclusions in the reticular formation, apparent calcification
of vessel walls in the globus pallidus, and cytoplasmic
eosinophilic inclusions in the thalamic nuclei.
On the other hand, the length of the CTG repeats of
the expanded allele did not show any considerable variations
depending on the brain region, with almost full length ex-
pansions and apparent somatic mosaicism even in the same
regions. In the cerebellar cortex and white matter of all of
the analyzed individuals, the expansion of the CTG repeats
and the somatic mosaicism were constantly the smallest
among all the brain regions studied. No correlation was
demonstrated between the region-specific CTG instability
and the severity of neuropathological changes throughout
the brain.
The features of the neuropathological changes associ-
ated with DM1 are not well established. NFTs were often
observed, mostly in the mesolimbic areas [28, 34], charac-
terized by a reduced expression of tau isoforms, including
the encoded sequences of exons 2, 3, 6 and 10 [18, 19,
30, 34]. In our study, NFTs were constantly observed in
the hippocampus and entorhinal cortex in all of the analyzed
DM1 cases. Other authors have reported intracytoplasmic
inclusion bodies in the thalamus and substantia nigra [25],
increased Marinesco bodies, and neuronal loss of the
medullary arcuate nucleus and reticular formation [26, 27].
However, it is unlikely that these contribute to the cognitive
impairment seen in DM1. The neuropathological changes
seen in autopsy cases of DM1 have included neuronal loss in
the superficial layer of the frontal and parietal cortices and
extensive neuronal loss in the occipital cortex, intracyto-
plasmic inclusion bodies in the medial thalamic nuclei,
neuronal loss and presence of Lewy bodies in the substantia
nigra, and locus coeruleus and abnormalities of myelin (i.e.
tigroid pattern) in the white matter [23, 29]. Lewy bodies
in the substantia nigra and locus coeruleus were frequently
but inconsistently seen in DM1. These changes, therefore,
were considered not to be specific for DM1. Previous reports
on cranial magnetic resonance imaging (MRI) findings in
DM1 described a wide variety of abnormalities ranging from
white matter hyperintense lesions (WML) to cerebral atro-
phy [9, 13, 24]. Some authors reported that large convexity
Virchow-Robin spaces were significantly associated with
DM1 and negatively correlated with the duration of disease,
which might precede the appearance of WMLs and brain
atrophy as one of the initial features of white matter involve-
ment in the disease [8]. It might be argued that WMLs
detected by MRI coincide with diffuse or perivascular loss
of myelin associated with vascular hyalinization and en-
larged perivascular spaces, which we observed in this
study. In addition to MRI findings, cerebral hypoperfusion
detected by single photon emission computed tomography
and cerebral hypometabolism detected by positron emission
tomography have also been reported in DM1 patients [1, 12,
20]. Taken together, it is considered that instances of état
criblé in the cerebral white matter are a morphological
change specific to DM1 brains, and likely responsible for
the subcortical dementia associated with DM1. The patho-
genetic mechanisms of WML are uncertain, and further
studies on the vascular changes are necessary.
Recent studies have suggested that both the myopathy
and CNS symptoms seen in DM1 reflect a toxic gain-of-
function due to mutant RNA [5–7, 10, 11, 14, 15, 17–19, 22,
Table 2.   Expanded ratios: expanded allele size to normal allele
one of DMPK locus
p<0.01, one-way ANOVA.
WBC, white blood cell; FG, frontal grey matter; FW, frontal white
matter; OrG, orbital grey mater; OrW, orbital white matter; PG,
parietal grey matter; PW, parietal white matter; OcG, occipital grey
matter; OcW, occipital white matter; TG, temporal grey matter; TW,
temporal white matter; Hip, hippocampus; NC, nucleus caudatus;
Put, putamen; GP, globus pallidus; Thal, thalamus; SN, substantia
nigra; NR, nucleus ruber; NP, nuclei pontis; VP, ventral pons; NOI,
nucleus olivaris inferior; Cer, cerebellum; DN, nucleus dentatus; Sp,
spinal cord; ND, not done.
case 1 case 4 case 5 case 6 case 9 mean SD
Normal allele 1.0 1.0 1.0 1.0 1.0
WBC 1.3 1.5 1.3 1.7 1.3 1.4±0.2
FG 1.9 2.5 1.8 2.3 1.9 2.1±0.3
FW 1.7 2.5 1.6 2.2 2.0 2.0±0.4
OrG 1.8 2.5 1.7 2.1 2.0 2.0±0.3
OrW 1.8 2.6 1.6 2.2 1.9 2.0±0.4
PG 2.1 2.6 1.7 2.3 2.1 2.2±0.3
PW 1.8 2.5 1.7 2.1 1.9 2.0±0.3
OcG 1.9 2.7 1.7 2.3 2.1 2.1±0.4
OcW 1.8 2.6 1.6 2.2 1.9 2.0±0.4
TG 1.9 2.5 1.7 2.3 2.0 2.1±0.3
TW 1.8 2.5 1.6 2.2 2.0 2.0±0.3
Hip 2.0 ND 1.9 2.3 1.7 2.0±0.3
NC 2.0 2.5 1.8 2.2 1.8 2.1±0.3
Put 1.8 2.4 1.8 2.2 1.7 2.0±0.3
GP 1.8 2.5 1.8 2.2 1.7 2.0±0.3
Thal 2.0 2.5 1.8 2.3 1.7 2.1±0.3
SN 2.1 2.4 1.8 2.1 1.7 2.0±0.3
NR 1.8 ND 1.7 2.2 1.8 1.9±0.2
NP 2.4 2.8 2.4 2.8 1.7 2.4±0.4
VP 1.8 2.8 1.7 2.1 1.8 2.0±0.5
NOI 1.7 2.4 1.8 2.3 1.9 2.0±0.3
Cer 1.1 1.2 1.1 1.2 1.1 1.1±0.1*
DN 1.1 1.3 ND 1.2 1.5 1.3±0.2
Sp 1.9 ND 1.7 2.1 1.7 1.9±0.2Neuropathology and CTG Repeats in MD1 155
31–33]. In those studies, the CUG repeats in the mutant
transcript were highly expanded but the portion of the
mRNA encoding DMPK remained intact. CUG-expanded
transcripts were retained in cell nuclei as focal inclusions.
The accumulation of mutant RNA in the neuronal nucleus
compromises the regulation of alternative splicing for a
subset of neuronal transcripts and may also disrupt the regu-
lation of transcription in general. Dhaenens et al. showed
that adult DM1 brain exhibits overexpression of MBNL1
fetal isoforms and modified splicing of tau pre mRNA,
resulting in the aggregation of tau isoforms that lack exon
2/3 encoded sequences [7]. Examination of post-mortem
DM1 brain tissue by fluorescence in situ hybridization in-
dicated that the mutant DMPK mRNA, with its expanded
CUG repeats in the 3'-untranslated region, was widely
expressed in cortical and subcortical neurons [15]. The
mutant transcripts accumulated in discrete foci within
the neuronal nuclei. Proteins in the muscleblind family
(MBL1, MBL2) were recruited into the RNA foci and
depleted elsewhere in the nucleoplasm. In parallel, a sub-
set of neuronal pre-mRNAs, including tau, NMDA NR1
receptor, and amyloid precursor protein, showed abnormal
regulation of alternative splicing. This report showed widely
distributed RNA foci in the neurons from cerebral cortices,
hippocampus, dentate gyrus, thalamus, substantia nigra and
brainstem tegmentum, and less intensely in oligodendro-
cytes of the subcortical white matter and corpus callosum.
The exception was the cerebellar cortex, where small foci
were detected in some Purkinje cells, but not in neurons
in the granular layer. This might be compatible with the
findings of present study showing that CTG repeats were
smaller in the cerebellar cortex in DM1 cases, because the
dominant cellular component of cerebellar cortex is granule
cells. Further study will be needed to clarify this issue.
The expansion of the CTG repeats showed considerable
homogeneity in all of the brain regions examined, except
for the cerebellar cortex in the DM1 cases. On the other
hand, the pathological changes were more heterogeneous,
including ischemic changes of the white matter, tauopathy in
the mesolimbic region, as well as Lewy bodies and NFT in
the brainstem. The length of the CTG repeats was not
parallel to the morphological changes, which suggested
that the pathomechanisms of DM1 might be more complex
and multifactorial rather than a toxic gain-of-function due to
mutant RNA.
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